Abstract
Alzheimers disease (AD) is characterized by the presence of extracellular amyloid plaques, containing the extracellular amorphous deposits of beta-amyloid protein and intracellular neurofibrillary tangles, comprising filaments of phosphorylated form of a microtubule-associated protein Tau, localized in the brain. It is considered that the major constituent of amyloid plaques, beta-amyloid peptide (Aβ), induces AD neuropathology. AD enzymatic pathway comprises several events: (i) beta-secretase cleaves amyloid precursor protein (APP) and releases a soluble fragment, beta-APPs, and (ii) gamma-secretase cleaves the C-terminal membrane bound C99 peptide within the transmembrane domain, thus generating two major amino acid isoforms of beta-amyloid: Aβ40 and Aβ42. This review is focused on the recent advances in the field of computational chemistry (molecular docking, 3D-QSAR (CoMFA (Comparative Molecular Field Analysis) and CoMSIA (Comparative Molecular Similarity Indices Analysis)), molecular dynamics and rational drug design) applied to inhibitions of beta and gamma secretases. Computational chemistry studies have been performed for different inhibitors of beta and gamma secretases (e.g. benzodiazepine, urethane and tetrapeptide derivatives) resulting in their predicted biological activities and free energies.
Keywords: Alzheimer's disease, gamma and beta secretases inhibition, computational chemistry
Current Enzyme Inhibition
Title: Computer-Aided Drug Design Applied to Beta and Gamma Secretase Inhibitors-Perspectives for New Alzheimer Disease Therapy
Volume: 2 Issue: 4
Author(s): Speranta Avram, Adina L. Milac, Dan F. Mihailescu, Aurelia Dabu and Maria L. Flonta
Affiliation:
Keywords: Alzheimer's disease, gamma and beta secretases inhibition, computational chemistry
Abstract: Alzheimers disease (AD) is characterized by the presence of extracellular amyloid plaques, containing the extracellular amorphous deposits of beta-amyloid protein and intracellular neurofibrillary tangles, comprising filaments of phosphorylated form of a microtubule-associated protein Tau, localized in the brain. It is considered that the major constituent of amyloid plaques, beta-amyloid peptide (Aβ), induces AD neuropathology. AD enzymatic pathway comprises several events: (i) beta-secretase cleaves amyloid precursor protein (APP) and releases a soluble fragment, beta-APPs, and (ii) gamma-secretase cleaves the C-terminal membrane bound C99 peptide within the transmembrane domain, thus generating two major amino acid isoforms of beta-amyloid: Aβ40 and Aβ42. This review is focused on the recent advances in the field of computational chemistry (molecular docking, 3D-QSAR (CoMFA (Comparative Molecular Field Analysis) and CoMSIA (Comparative Molecular Similarity Indices Analysis)), molecular dynamics and rational drug design) applied to inhibitions of beta and gamma secretases. Computational chemistry studies have been performed for different inhibitors of beta and gamma secretases (e.g. benzodiazepine, urethane and tetrapeptide derivatives) resulting in their predicted biological activities and free energies.
Export Options
About this article
Cite this article as:
Avram Speranta, Milac L. Adina, Mihailescu F. Dan, Dabu Aurelia and Flonta L. Maria, Computer-Aided Drug Design Applied to Beta and Gamma Secretase Inhibitors-Perspectives for New Alzheimer Disease Therapy, Current Enzyme Inhibition 2006; 2 (4) . https://dx.doi.org/10.2174/157340806778699307
DOI https://dx.doi.org/10.2174/157340806778699307 |
Print ISSN 1573-4080 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6662 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Understanding the Complexities of Functional Ability in Alzheimer’s Disease: More Than Just Basic and Instrumental Factors
Current Alzheimer Research Immunomodulatory Properties of Farnesoids: The New Steroids?
Current Medicinal Chemistry Current and Promising Pharmacotherapies, and Novel Research Target Areas in the Treatment of Alcohol Dependence: A Review
Current Pharmaceutical Design Neuronal Nicotinic Acetylcholine Receptors as Pharmacotherapeutic Targets for the Treatment of Alcohol Use Disorders
CNS & Neurological Disorders - Drug Targets Stem Cell and Idiopathic Pulmonary Fibrosis: Mechanisms and Treatment
Current Stem Cell Research & Therapy The Aftermath of Childhood Sexual Abuse: A Case Report and Review of the Literature
Adolescent Psychiatry The Role of Oxytocin in Autism Spectrum Disorders
Current Psychopharmacology Bromelain Degrades Aβ1-42 Monomers and Soluble Aggregates: An In Vitro Study in Cerebrospinal Fluid of Alzheimer’s Disease Patients
Current Alzheimer Research Quality, not Quantity: The Role of Natural Products and Chemical Proteomics in Modern Drug Discovery
Combinatorial Chemistry & High Throughput Screening Different Inflammatory Biomarker Patterns in the Cerebro-Spinal Fluid Following Heart Surgery and Major Non-Cardiac Operations
Current Drug Metabolism Recent Advances in Sepsis Research: Novel Biomarkers and Therapeutic Targets
Current Medicinal Chemistry Gene Therapy in the Transplantation of Allogeneic Organs and Stem Cells
Current Gene Therapy Development of a Non Invasive NGF-Based Therapy for Alzheimers Disease
Current Alzheimer Research Subject Index to Volume 1
Current Pharmacogenomics Sex Hormones and their Analogues in Neuroimmune Biology
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Bioavailability Enhancement of Rizatriptan Benzoate by Oral Disintegrating Strip: In vitro and In vivo Evaluation
Current Drug Delivery Asymptomatic Primary Hyperparathyroidism: Management and Implications
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Astrocytic Expression of the Immunoreceptor CD300f Protects Hippocampal Neurons from Amyloid-β Oligomer Toxicity In Vitro
Current Alzheimer Research Array-Comparative Genomic Hybridization Analysis of a Cohort of Saudi Patients with Epilepsy
CNS & Neurological Disorders - Drug Targets Therapeutic Prospects for the Prevention of Neurodegeneration in Huntingtons Disease and the Polyglutamine Repeat Disorders
Mini-Reviews in Medicinal Chemistry